The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumResearch - Just as investors were getting comfortable with bluebird bio’s (BLUE) most recent disappointment, it’s happened again. Today at the American Society of Hematology’s annual meeting, bluebird revealed updated results from HGB-206, the company’s small phase 1/2 study dedicated exclusively to treating Sickle Cell Disease patients with LentiGlobin.
PremiumResearch - Street Insider reported on Friday afternoon that Merck (MRK) plans to make an offer for Relypsa (RLYP). FT Alphaville is confirming with a similar story, citing GlaxoSmithKline … Continue Reading
PremiumResearch - Cellectis/treating physicians will discuss the first-in-human experience with UCART19, the company's allogeneic CD-19 targeted CAR-T asset, at ASH. And, they may be able to discuss results in more than one patient.
PremiumResearch - The recovery is slowly underway in the land of biotech, and these equities are getting a lift from Pfizer's (PFE) planned merger with Allergan (AGN), announced Monday.
Read nowInsights - The event of the week - some would argue the event of the year - was the release of FDA briefing documents related to BioMarin's (BMRN) drisapersen, which faces an FDA advisory committee meeting this coming Tuesday. The drug is up for approval in Duchenne Muscular Dystrophy next month, and the upcoming committee meeting is all about FDA getting input from outside experts on the risk/benefit of approving drisapersen for DMD patients amenable to treatment by exon 51 skipping, drisapersen's mechanism of action.
Read nowInsights - The markets took a rapid turn lower this week, which should come as no surprise to those who’ve watched equities’ equally swift rally over the … Continue Reading
Read nowResearch - Bellicum Pharmaceuticals (BLCM) after the bell this evening reported third quarter earnings, but more importantly noted that four pediatric beta-thalassemia patients who underwent HSCT followed by BPX-501 modified T cells are transfusion-free.
Premium
